Cowen and Company upgraded shares of Mylan (NASDAQ:MYL) from a market perform rating to an outperform rating in a research report sent to investors on Monday morning, ARN reports. The firm currently has $45.00 price target on the stock, up from their previous price target of $29.00.
Cowen and Company has also taken action a number of other stocks recently. The firm lowered its price target on shares of Barrick Gold Corp from $18.10 to $17.61. They have a market perform rating on that stock. Also, Cowen and Company lowered its price target on shares of Yamana Gold from C$13.33 to C$12.86. They have an outperform rating on that stock. Finally, Cowen and Company raised its price target on shares of Weatherford from $19.00 to $20.00. They have an outperform rating on that stock.
A number of other firms have also recently commented on MYL. Analysts at BMO Capital Markets raised their price target on shares of Mylan from $21.00 to $25.00 in a research note to investors on Monday. They now have an underperform rating on the stock. Separately, analysts at UBS AG raised their price target on shares of Mylan from $36.00 to $39.00 in a research note to investors on Friday, August 2nd. They now have a buy rating on the stock. Finally, analysts at Needham & Company downgraded shares of Mylan from a strong-buy rating to a buy rating in a research note to investors on Friday, August 2nd. They now have a $40.00 price target on the stock, up previously from $34.00.
One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Mylan has an average rating of Buy and an average target price of $37.15.
Mylan (NASDAQ:MYL) traded up 0.52% on Monday, hitting $37.01. Mylan has a 1-year low of $23.04 and a 1-year high of $37.10. The stock’s 50-day moving average is currently $32.15. The company has a market cap of $14.108 billion and a price-to-earnings ratio of 22.59.
Mylan, Inc develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.